Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.

Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninf

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile